News

 

 

Recently Opened Clinical Trials

Marc Ernstoff
Professor
Immunology and Cancer Immunotherapy

Alliance – NCI Cooperative Group
Randomized Phase II study comparing cabozantinib (Nsc #761968 And Ind #116059) with commercially supplied sunitinib in patients with previously untreated locally advanced or metastatic renal cell carcinoma

Camilo E. Fadul
Professor
Immunology and Cancer Immunotherapy

Alliance – NCI Cooperative Group
A Phase II randomized trial comparing the efficacy of heat shock protein-peptide complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND# 15380) vaccine given with bevacizumab versus bevacizumab alone in the treatment of surgically resectable recurrent Glioblastoma Multiforme (GBM)

Peter A. Kaufman
Associate Professor
Molecular Therapeutics

Eisai
A Phase II, single-arm, feasibility study of dose dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate for the adjuvant treatment of early stage breast cancer

Frederick Lansigan
Assistant Professor
Molecular Therapeutics

ECOG
Intergroup randomized Phase II four arm study in patients = 60 with previously untreated mantle cell lymphoma of therapy with: Arm A = rituximab+ bendamustine followed by rituximab consolidation (RB -> R); Arm B = rituximab + bendamustine + bortezomib followed by rituximab consolidation (RBV -> R), Arm C = rituximab + bendamustine followed by lenalidomide + rituximab consolidation (RB -> LR) or Arm D = rituximab + bendamustine + bortezomib followed by lenalidomide + rituximab consolidation (RBV -> LR)

Alopexx
A Phase I study of De-immunized DI-Leu16-IL2 Immunocytokine administered subcutaneously in patients with B-cell Non-Hodgkin Lymphoma (NHL)

Lionel Lewis
Professor
Molecular Therapeutics

AbbVie
An extension study of ABT-199 in subjects with advanced non-hodgkin's lymphoma

AbbVie
A Phase 1 study to assess the effect of ketoconazole on the pharmacokinetics of ABT-199